Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle.

Dunnick JK, Singh B, Nyska A, Peckham J, Kissling GE, Sanders JM.

Toxicol Pathol. 2011 Feb;39(2):398-409. doi: 10.1177/0192623310394211. Epub 2011 Feb 7.

PMID:
21300790
2.
3.

Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies).

National Toxicology Program.

Natl Toxicol Program Tech Rep Ser. 2011 May;(565):1-177. Review.

4.

Variations in alkaloid content of herbal products containing goldenseal.

Edwards DJ, Draper EJ.

J Am Pharm Assoc (2003). 2003 May-Jun;43(3):419-23.

PMID:
12836794
5.

The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.

Albassam AA, Frye RF, Markowitz JS.

Chem Biol Interact. 2017 Jun 1;271:24-29. doi: 10.1016/j.cbi.2017.04.025. Epub 2017 Apr 27.

PMID:
28457856
6.

Chemical comparison of goldenseal (Hydrastis canadensis L.) root powder from three commercial suppliers.

Weber HA, Zart MK, Hodges AE, Molloy HM, O'Brien BM, Moody LA, Clark AP, Harris RK, Overstreet JD, Smith CS.

J Agric Food Chem. 2003 Dec 3;51(25):7352-8.

PMID:
14640583
7.

Mechanism study of goldenseal-associated DNA damage.

Chen S, Wan L, Couch L, Lin H, Li Y, Dobrovolsky VN, Mei N, Guo L.

Toxicol Lett. 2013 Jul 31;221(1):64-72. doi: 10.1016/j.toxlet.2013.05.641. Epub 2013 Jun 5.

8.

Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.). 2. Palmatine, hydrastine, canadine, and hydrastinine.

Inbaraj JJ, Kukielczak BM, Bilski P, He YY, Sik RH, Chignell CF.

Chem Res Toxicol. 2006 Jun;19(6):739-44.

PMID:
16780351
9.

NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).

National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,.

Natl Toxicol Program Tech Rep Ser. 2004 May;(512):7-289.

10.
11.

Method validation for determination of alkaloid content in goldenseal root powder.

Weber HA, Zart MK, Hodges AE, White KD, Barnes SM, Moody LA, Clark AP, Harris RK, Overstreet JD, Smith CS.

J AOAC Int. 2003 May-Jun;86(3):476-83.

PMID:
12852562
12.

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.

Cufí S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, Bosch-Barrera J, Joven J, Micol V, Menendez JA.

Food Chem Toxicol. 2013 Oct;60:360-8. doi: 10.1016/j.fct.2013.07.063. Epub 2013 Aug 1.

PMID:
23916468
13.

Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.

Hermann R, von Richter O.

Planta Med. 2012 Sep;78(13):1458-77. doi: 10.1055/s-0032-1315117. Epub 2012 Aug 1. Review.

14.

An ex vivo approach to botanical-drug interactions: a proof of concept study.

Wang X, Zhu HJ, Munoz J, Gurley BJ, Markowitz JS.

J Ethnopharmacol. 2015 Apr 2;163:149-56. doi: 10.1016/j.jep.2015.01.021. Epub 2015 Jan 24.

15.

Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ.

Cancer Res. 2005 May 15;65(10):4448-57.

16.
17.
18.
19.

Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246-96-0) in F344/N rats and B6C3F1 mice (gavage studies).

National Toxicology Program.

Natl Toxicol Program Tech Rep Ser. 2003 May;(508):1-280.

20.

Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse.

Verschoyle RD, Brown K, Steward WP, Gescher AJ.

Cancer Chemother Pharmacol. 2008 Jul;62(2):369-72. Epub 2007 Oct 2.

PMID:
17909802

Supplemental Content

Support Center